116 related articles for article (PubMed ID: 12834817)
1. NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia.
Hori H; Ohmori O; Matsumoto C; Shinkai T; Nakamura J
Psychiatry Res; 2003 Jun; 118(3):235-9. PubMed ID: 12834817
[TBL] [Abstract][Full Text] [Related]
2. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.
Pae CU; Yu HS; Kim JJ; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH
Int J Neuropsychopharmacol; 2004 Dec; 7(4):495-500. PubMed ID: 15151706
[TBL] [Abstract][Full Text] [Related]
3. Genetic association of NAD(P)H quinone oxidoreductase (NQO1*2) polymorphism with NQO1 levels and risk of diabetic nephropathy.
Sharma M; Mehndiratta M; Gupta S; Kalra OP; Shukla R; Gambhir JK
Biol Chem; 2016 Aug; 397(8):725-30. PubMed ID: 27078674
[TBL] [Abstract][Full Text] [Related]
4. No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.
Hori H; Shinkai T; Matsumoto C; Ohmori O; Nakamura J
Neuromolecular Med; 2006; 8(3):375-80. PubMed ID: 16775388
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones.
Joseph P; Jaiswal AK
Br J Cancer; 1998 Mar; 77(5):709-19. PubMed ID: 9514048
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements.
Lanciotti M; Dufour C; Corral L; Di Michele P; Pigullo S; De Rossi G; Basso G; Leszl A; Luciani M; Lo Nigro L; Micalizzi C; Valsecchi MG; Biondi A; Haupt R
Leukemia; 2005 Feb; 19(2):214-6. PubMed ID: 15618957
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
[TBL] [Abstract][Full Text] [Related]
8. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
9. Quinone oxidoreductase (NQO1) gene polymorphism may not confer a susceptibility to mood disorders.
Pae CU; Yoon SJ; Patkar AA; Kim JJ; Lee C; Paik IH
Psychiatry Res; 2007 Sep; 153(1):83-6. PubMed ID: 17644186
[TBL] [Abstract][Full Text] [Related]
10. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects.
Akkiz H; Bayram S; Bekar A; Akgöllü E; Ülger Y; Kaya BY; Sandikçi M; Özdil B
Asian Pac J Cancer Prev; 2010; 11(4):1051-8. PubMed ID: 21133623
[TBL] [Abstract][Full Text] [Related]
11. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
Ross D; Kepa JK; Winski SL; Beall HD; Anwar A; Siegel D
Chem Biol Interact; 2000 Dec; 129(1-2):77-97. PubMed ID: 11154736
[TBL] [Abstract][Full Text] [Related]
12. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
[TBL] [Abstract][Full Text] [Related]
14. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity.
Moran JL; Siegel D; Ross D
Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8150-5. PubMed ID: 10393963
[TBL] [Abstract][Full Text] [Related]
15. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan.
Liou YJ; Wang YC; Lin CC; Bai YM; Lai IC; Liao DL; Chen JY
Int J Neuropsychopharmacol; 2005 Sep; 8(3):483-6. PubMed ID: 15836802
[No Abstract] [Full Text] [Related]
16. The association between NQO1 Pro187Ser polymorphism and bladder cancer susceptibility: a meta-analysis of 15 studies.
Yang S; Jin T; Su HX; Zhu JH; Wang DW; Zhu SJ; Li S; He J; Chen YH
PLoS One; 2015; 10(1):e0116500. PubMed ID: 25602258
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.
Lafuente MJ; Casterad X; Trias M; Ascaso C; Molina R; Ballesta A; Zheng S; Wiencke JK; Lafuente A
Carcinogenesis; 2000 Oct; 21(10):1813-9. PubMed ID: 11023538
[TBL] [Abstract][Full Text] [Related]
18. Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia.
Pae CU
Psychiatry Res; 2008 Dec; 161(3):336-8. PubMed ID: 18977034
[TBL] [Abstract][Full Text] [Related]
19. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan.
Wang YH; Lee YH; Tseng PT; Shen CH; Chiou HY
J Cancer Res Clin Oncol; 2008 Feb; 134(2):203-9. PubMed ID: 17619904
[TBL] [Abstract][Full Text] [Related]
20. A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer.
Begleiter A; Hewitt D; Maksymiuk AW; Ross DA; Bird RP
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2422-6. PubMed ID: 17164365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
